Somewhat Positive Press Coverage Somewhat Unlikely to Affect REGENXBIO (RGNX) Stock Price
News headlines about REGENXBIO (NASDAQ:RGNX) have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. REGENXBIO earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.1650055387958 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the headlines that may have impacted Accern’s scoring:
- REGENXBIO Inc. (RGNX) Coverage Initiated by Analysts at Barclays PLC (americanbankingnews.com)
- Kenneth T. Mills Sells 10,000 Shares of REGENXBIO Inc. (RGNX) Stock (americanbankingnews.com)
- REGENXBIO Inc. (RGNX) Downgraded to Hold at Zacks Investment Research (americanbankingnews.com)
- Five Prime Therapeutics (FPRX) versus REGENXBIO (RGNX) Head to Head Contrast (americanbankingnews.com)
Shares of REGENXBIO (NASDAQ:RGNX) opened at $29.70 on Thursday. REGENXBIO has a 1-year low of $16.30 and a 1-year high of $36.10.
REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.04. The company had revenue of $1.34 million for the quarter. REGENXBIO had a negative net margin of 764.06% and a negative return on equity of 39.33%. analysts anticipate that REGENXBIO will post -2.71 earnings per share for the current fiscal year.
Several equities analysts recently weighed in on the stock. Barclays PLC assumed coverage on shares of REGENXBIO in a research report on Wednesday. They issued an “overweight” rating and a $38.00 price target on the stock. BidaskClub raised shares of REGENXBIO from a “hold” rating to a “buy” rating in a research report on Saturday, August 12th. Zacks Investment Research raised shares of REGENXBIO from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research report on Saturday, August 12th. Evercore ISI assumed coverage on shares of REGENXBIO in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $25.00 price target on the stock. Finally, ValuEngine cut shares of REGENXBIO from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $42.43.
In related news, insider Kenneth T. Mills sold 10,500 shares of REGENXBIO stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $25.00, for a total value of $262,500.00. Following the completion of the transaction, the insider now directly owns 118,530 shares in the company, valued at approximately $2,963,250. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Stephen Yoo sold 32,658 shares of REGENXBIO stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $25.00, for a total transaction of $816,450.00. Following the completion of the transaction, the insider now owns 31,803 shares of the company’s stock, valued at $795,075. The disclosure for this sale can be found here. Insiders sold a total of 210,500 shares of company stock valued at $5,957,300 over the last quarter. 17.00% of the stock is owned by company insiders.
REGENXBIO Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Stock Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related stocks with our FREE daily email newsletter.